Drug evaluation:: ACP-103, a 5-HT2A receptor inverse agonist

被引：0
|
作者：
Roberts, Claire [1 ]
机构：
[1] GlaxoSmithKline Plc, Psychiat Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England
来源：
CURRENT OPINION IN INVESTIGATIONAL DRUGS | 2006年 / 7卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
ACADIA Pharmaceuticals is developing ACP-103, lead compound in a series of 5-HT2A inverse agonists, as a potential antipsychotic agent and for the potential treatment of insomnia. Phase II clinical trials in treatment-induced psychosis in Parkinson's disease (PD) patients and in schizophrenic patients are ongoing, as are phase II trials evaluating the effects of the drug on PD symptoms and dyskinesias.
引用
收藏
页码：653 / 660
页数：8
相关论文
共 50 条
  • [1] ACP-103, a 5-HT2A receptor inverse agonist, as an adjunctive therapy in schizophrenia
    Vanover, Kimberly E.
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 101 : 43 - 43
  • [2] ACP-103, a potent 5-HT2A receptor inverse agonist, as an adjunctive therapy in schizophrenia
    Vanover, Kimberly E.
    Lameh, Jelveh
    Gardell, Luis R.
    Ott, Thomas R.
    Ma, Jian-Nong
    Burstein, Ethan S.
    van Kammen, Daniel
    Davis, Robert E.
    Weiner, David M.
    Brann, Mark R.
    [J]. ACTA PHARMACOLOGICA SINICA, 2006, 27 : 80 - 80
  • [3] PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain
    Nordstrom, Anna-Lena
    Mansson, Mattias
    Jovanovic, Hristina
    Karlsson, Per
    Halldin, Christer
    Farde, Lars
    Vanover, Kimberly E.
    Hacksell, Uli
    Brann, Mark R.
    Davis, Robert E.
    Weiner, David M.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 (02): : 163 - 171
  • [4] ACP-103, a 5-HT2A receptor inverse agonist, a novel potential treatment for psychosis
    Vanover, KE
    Weiner, DM
    Harvey, SC
    Powell, SB
    Geyer, MA
    Andersson, CM
    Tolf, BR
    Hacksell, U
    Brann, MR
    Davis, RE
    [J]. SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 317 - 317
  • [5] The tolerability of ACP-103, a 5-HT2A receptor inverse agonist in Parkinson's disease patients
    Weiner, DM
    Vanover, KE
    Hacksell, U
    Brann, MR
    Davis, RE
    [J]. MOVEMENT DISORDERS, 2005, 20 : S72 - S72
  • [6] ACP-103, a 5-HT2A receptor inverse agonist: Safety, tolerability, and pharmacokinetics in healthy volunteers
    Vanover, KE
    Weiner, DM
    Schlienger, N
    Thygesen, M
    Tolf, B
    Hacksell, U
    Brann, MR
    Davis, RE
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S253 - S253
  • [7] ACP-103 -: 5-HT2A receptor inverse agonist -: Treatment of psychosis -: Treatment of sleep disorders
    Wang, Y.
    Bolos, J.
    Serradell, N.
    [J]. DRUGS OF THE FUTURE, 2006, 31 (11) : 939 - 943
  • [8] ACP-103, a novel 5-HT2A receptor inverse agonist, improves the efficacy and side effect profile of haloperidol in experimental models
    Gardell, LR
    Barido, RL
    Pounds, L
    Johnson, RW
    Anderson, GT
    Veinbergs, I
    Bonhaus, DW
    Hacksell, U
    Brann, MR
    Davis, RE
    Vanover, KE
    [J]. SCHIZOPHRENIA RESEARCH, 2006, 81 : 49 - 49
  • [9] A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model
    Vanover, Kimberly E.
    Betz, Adrienne J.
    Weber, Suzanne M.
    Bibbiani, Francesco
    Kielaite, Aiste
    Weiner, David M.
    Davis, Robert E.
    Chase, Thomas N.
    Salamone, John D.
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2008, 90 (04) : 540 - 544
  • [10] 5-HT2A receptor occupancy and pharmacodynamic measures at plasma steady state with ACP-103
    Vanover, K.
    Weiner, D.
    Davis, R.
    van Kammen, D.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S251 - S252
12345